Ashutosh Chilkoti
Duke University, USA

Ashutosh Chilkoti is the Alan L. Kaganov Professor and the Chair of the Department of Biomedical Engineering at Duke University. His areas of research include genetically encoded materials and biointerface science. He has pioneered the development of the first artificial polypeptides to enter clinical trials for drug delivery that provide a genetically encoded, injectable system for sustained delivery of protein drugs. He also invented a new method to purify protein drugs without chromatography, and developed an innovative technology for point-of-care clinical diagnostics. He was awarded the Clemson Award for Contributions to the Literature by the Society for Biomaterials in 2011, the Robert A. Pritzker Distinguished Lecture award by the Biomedical Engineering Society in 2013, was elected to the National Academy of Inventors in 2014, received the Distinguished Alumni award from the Indian Institute of Technology, Delhi in 2015, and the Diamond award from the College of Engineering at the University of Washington in 2017, and was elected to the American Association for the Advancement of Science in 2020. He is a fellow of American Institute of Medical and Biological Engineering, the Biomedical Engineering Society, and the Controlled Release Society, He is the founder of five start-up companies: (1) PhaseBio Pharmaceuticals, a publicly traded company on NASDAQ (sticker: PHAS) that is taking drug delivery technology that he developed into clinical trials; (2) Sentilus, a clinical diagnostics company that was acquired by Immucor in 2014; (3) GatewayBio, that is commercializing a next-generation PEGylation technology for biologics; (4) Isolere Bio that is developing a non-chromatographic technology for purification of monoclonal antibodies; and (5) inSoma Bio that is developing a recombinant protein matrix for tissue reconstruction.